ClinicalTrials.gg
CompletedNCT05704114Updated Jan 30, 2023

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

A Phase 4 interventional study of Tazarotene 0.045% Lotion in Acne Vulgaris, Post Inflammatory Hyperpigmentation and Post Inflammatory Pigmentation Change, sponsored by Dr. Emmy Graber. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by Dr. Emmy Graber · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 17 studies testing tazarotene in Acne Vulgaris — none open to participants now, none under way, none of them phase 3. tazarotene · Acne Vulgaris.

Enrollment
17th of 17
20 · median 210
Started
2021
the only one that year
Phase 4
4 of 17
none open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Dr. Emmy Graber

Among the 17 studies testing tazarotene in Acne Vulgaris, this one is the 17th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 4, and was the 17th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 17 studies testing tazarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

Where they have run

About tazarotene

tazarotene: first FDA approval 1997 (TAZORAC). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing tazarotene in Acne Vulgaris as a file.
02

Study summary

The purpose of the study is to assess the safety and efficacy of Arazlo Lotion (Tazarotene 0.045% Lotion) for treatment of postinflammatory erythema and postinflammatory hyperpigmentation in subjects with acne.

Read the detailed description

This research study is studying Arazlo Lotion (Tazarotene 0.045% Lotion) as a possible treatment for treating postinflammatory erythema (skin reddening) and postinflammatory hyperpigmentation (dark skin spots) secondary to acne. Up to 20 people at the study doctor's office will be enrolled. Bausch Health USA is manufacturing the study drug in this research study.

The participants are being asked to participate in this research study because the participants have postinflammatory erythema and/or postinflammatory hyperpigmentation secondary to acne.

Postinflammatory erythema (PIE) is defined as the blanchable (turns white when pressed) red or pink macule (discolored spot) seen after an acne lesion (skin sore) resolves. PIE has been considered to be stage I scarring by some; however, PIE is not permanent but may be the preceding lesion for some atrophic (indented) scars. PIE is exceedingly common and is seen more in lighter skin types (I-III) and is often incorrectly considered by health care providers to be hyperpigmentation. PIE is nearly ubiquitous in acne patients with fairer skin tones and is blanchable erythema rather than hyperpigmentation. It differs from postinflammatory hyperpigmentation (PIH), which is the formation of dark macules due to an overexpression of melanin (dark pigment) that is secondary to an inflammatory response. PIH is particularly common in dark-skinned individuals.

PIE has been reportedly treated with in office treatments such as: pulsed dye laser, 1,450-nm laser, or fractional microneedling with radiofrequency; however, these treatments are not perfect. They come at a high financial cost to the patient, are not without side effects, are not well studied, and their efficacy for PIE is questionable. There is no known topical treatment for PIE that is secondary to acne. Conversely, various topicals do exist to treat PIH that work by inhibiting tyrosinase (an enzyme responsible for the first step in producing melanin), such as topical retinoids (compounds similar to Vitamin A). One small study showed tazarotene 0.1% cream to be effective in improving PIH. However, there are also reports of tazarotene worsening PIH, likely due to the skin irritation caused by the high strength of the tazarotene.

Our intended purpose is to demonstrate that Arazlo Lotion can reduce the formation of PIE and PIH in acne patients. The investigators hypothesize that Arazlo Lotion prevents the formation of PIE and PIH and treats PIE and PIH from acne due to its anti-inflammatory properties. These same anti-inflammatory properties of topical retinoids have been proven to reduce active acne lesions. However, no one has investigated the role of Arazlo Lotion on PIE and PIH. Small studies have shown that tazarotene 0.1% have improved PIH but other case reports have shown it to cause PIH. Utilizing Arazlo Lotion, a lower strength of tazarotene, in a gentler formulation, the investigators believe will lessen PIH without causing irritation and therefore reduce any potential PIH sequelae (conditions).

A participant cannot join this study if the participant has more than 3 excoriated (picked lesions) acne lesions, a beard or extensive facial hair, are a female subject who is pregnant, nursing, or planning a pregnancy during the trial, or the study doctor feels the participant needs to be treated with acne medications that are taken by mouth (also called "oral" medications). This is a study for subjects with discoloration, PIE and PIH, secondary to acne. The goal of treatment in this study is for the participant's acne discoloration to improve, which is no different than if the participant were to see the study doctor without being in the study.

The participant will receive the study drug, Arazlo Lotion, and any other topicals (applied on the skin) required by the study and all study examinations at no charge. The participant will receive payment to cover the costs of the participant's time and expenses to go to the study doctor's office for the study.

03

Conditions studied

  • Acne Vulgaris
  • Post Inflammatory Hyperpigmentation
  • Post Inflammatory Pigmentation Change
  • Erythema
  • Skin Scarring

Keywords

  • Acne vulgaris
  • Post Inflammatory Hyperpigmentation
  • Post Inflammatory Pigmentation Change
  • Erythema
  • Acne scars
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is male or female, 18-45 years of age inclusive at Screening.
  • Must have a facial IGA score of 2,3, or 4.
  • Minimum of 10 inflammatory lesions (papules, pustules, or nodules) in total on face (including nose).
  • Minimum of 20 PIE or PIH macules in total on face (including nose).
  • Skin phototype of I to VI on Fitzpatrick's scale.
  • Female subjects of must be on one of the following forms of : a hormonal or non-hormonal IUD, an oral contraceptive pill that contains both estrogen and progestin, a contraceptive implant, or Depo shot. Patients will remain on the same contraception for 90 days prior to the baseline visit, for the duration of the study and for 1 month after.

Exclusion criteria

Exclusion Criteria:

  • More than 3 excoriated acne lesions.
  • Beard or extensive facial hair.
  • Female subject who is pregnant, nursing, or planning a pregnancy during the trial or within one month after last trial treatment application.
  • Isotretinoin within 90 days.
  • Other topical prescription retinoids (30 days wash out).
  • A new hormone or hormone regulating therapy (such as spironolactone or ), or change in an existing dosage, for any reason within 90 days prior to screening. A patient who has been using the same regimen for more than 90 days prior to the study may be enrolled but is expected to remain on said regimen for the duration of the study.
  • A new oral antibiotic or change in an existing dosage for any reason within 30 days prior to screening. A patient who has been using the same regiment for more than 30 days prior to the study may be enrolled but is expected to remain on the said regimen for the duration of the study.
  • A new or change in topical anti-acne agents within 60 days of starting the study. This includes topical medications such as: benzoyl peroxide, erythromycin, clindamycin, minocycline, clascoterone, and dapsone. Use of such agents is permitted as long as subjects have been using these topical agents for at least 60 days prior and willing to stay on them for the duration of the study.
  • Sebacia laser treatment within 180 days of study enrollment. Subjects may not have this treatment during the study.
  • Any facial laser treatment or chemical peel within one month of enrollment. Subjects may not have these treatments during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    This is a single arm study. All participants are receiving the treatment.

    Drug: Tazarotene 0.045% Lotion

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction of postinflammatory erythema lesion count.

    A count of postinflammatory erythema lesions will be conducted at each visit.

    Time frame: 16 weeks

  2. Reduction of postinflammatory hyperpigmentation lesion count.

    A count of postinflammatory hyperpigmentation lesions will be conducted at each visit.

    Time frame: 16 weeks

  3. Reduction of active acne lesion count

    Active acne lesions will be counted at each visit.

    Time frame: 16 weeks

Secondary outcomes

  1. Patient perceived improvement through completion of a patient satisfaction survey

    The patient will fill out a questionnaire at each visit.

    Time frame: 16 weeks

07

Study locations

1 site
  • The Dermatology Institute of Boston
    Boston, Massachusetts 02116, United States
08

References and documents

Publications

  • Tan J, Bourdes V, Bissonnette R, Petit B Eng L, Reynier P, Khammari A, Dreno B. Prospective Study of Pathogenesis of Atrophic Acne Scars and Role of Macular Erythema. J Drugs Dermatol. 2017 Jun 1;16(6):566-572. PubMed 28686774 ↗
  • Fabbrocini G, Annunziata MC, D'Arco V, De Vita V, Lodi G, Mauriello MC, Pastore F, Monfrecola G. Acne scars: pathogenesis, classification and treatment. Dermatol Res Pract. 2010;2010:893080. doi: 10.1155/2010/893080. Epub 2010 Oct 14. PubMed 20981308 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Feb 2022, 12 months.

Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Jan 30, 2023
StartActual
Feb 1, 2021
Primary completionActual
Feb 1, 2022
CompletionActual
May 1, 2022
Last update
Jan 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05704114
Lead sponsor
Dr. Emmy Graber
Responsible party
Dr. Emmy Graber (President of The Dermatology Institute of Boston, Principal Investigator, The Dermatology Institute of Boston) — Sponsor-investigator
First posted
Jan 30, 2023
Start date
Feb 1, 2021
Primary completion
Feb 1, 2022
Completion
May 1, 2022
Last update
Jan 30, 2023

Study contacts

Emmy Graber
principal investigator · The Dermatology Insitutue of Boston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tazarotene

Start the discussion